The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis

被引:106
作者
Dabiri, S
Huntsman, D
Makretsov, N
Cheang, M
Gilks, B
Bajdik, C
Gelmon, K
Chia, S
Hayes, M
机构
[1] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC V5Z 4E6, Canada
[2] Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Dept Pathol & Prostate Res Ctr, Vancouver, BC, Canada
[3] British Columbia Canc Agcy, Dept Epidemiol, Vancouver, BC V5Z 4E6, Canada
[4] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada
关键词
CD-117; c-kit; mast cells; immunostaining; prognosis;
D O I
10.1038/modpathol.3800094
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Tissue microarrays containing 348 cases of invasive breast carcinoma were studied by immunohistochemical staining for CD-117, CD-3, CD-20, CD-68, Her2, estrogen receptor protein, and progesterone receptor protein, and results were correlated with patient outcome. Hormone receptor status (both estrogen receptor and progesterone receptor) correlated with a good outcome while Her2 overexpression was associated with a poor outcome. The presence of mast cells in the stroma, as demonstrated by positive c-kit (CD-117) staining, correlated with a good prognosis (P=0.0036). On subset analysis, this association between the presence of mast cells and favorable prognosis was present in the node-negative patients (P = 0.018). The presence of mast cells showed an inverse correlation with the presence of CD-68 positive macrophages. No correlation was observed between the presence of mast cells and either B-cells (CD20-positive) or T-cells (CD3-positive). The presence of stromal mast cells was of prognostic significance independent of nodal status and tumor size (P=0.02). When the multivariate analysis was expanded to include tumor grade, estrogen receptor status and Her2 status, as well as tumor size and nodal status, the presence of stromal mast cells approached significance as an independent prognostic indicator.
引用
收藏
页码:690 / 695
页数:6
相关论文
共 25 条
[1]  
AALTOMAA S, 1993, ANTICANCER RES, V13, P785
[2]   Immunohistochemical studies of c-kit, transforming growth factor-β, and basic fibroblast growth factor in mast cell disease [J].
Baek, JY ;
Tefferi, A ;
Pardanani, A ;
Li, CY .
LEUKEMIA RESEARCH, 2002, 26 (01) :83-90
[3]   Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? [J].
Bowrey, PF ;
King, J ;
Magarey, C ;
Schwartz, P ;
Marr, P ;
Bolton, E ;
Morris, DL .
BRITISH JOURNAL OF CANCER, 2000, 82 (01) :167-170
[4]   Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues [J].
Chui, X ;
Egami, H ;
Yamashita, J ;
Kurizaki, T ;
Ohmachi, H ;
Yamamoto, S ;
Ogawa, M .
BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1233-1236
[5]   HISTAMINE AS AN AUTOCRINE GROWTH-FACTOR IN EXPERIMENTAL MAMMARY CARCINOMAS [J].
CRICCO, GP ;
DAVIO, CA ;
MARTIN, G ;
ENGEL, N ;
FITZSIMONS, CP ;
BERGOC, RM ;
RIVERA, ES .
AGENTS AND ACTIONS, 1994, 43 (1-2) :17-20
[6]   PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].
ELSTON, CW ;
ELLIS, IO .
HISTOPATHOLOGY, 1991, 19 (05) :403-410
[7]   TISSUE MAST-CELLS IN BREAST-CANCER [J].
FISHER, ER ;
SASS, R ;
WATKINS, G ;
JOHAL, J ;
FISHER, B .
BREAST CANCER RESEARCH AND TREATMENT, 1985, 5 (03) :285-291
[8]   Testing for KIT (CD117) in gastrointestinal stromal tumors - Another HercepTest? [J].
Fletcher, CDM ;
Fletcher, JA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (02) :163-164
[9]   CD 117 (KIT): A diverse protein with selective applications in surgical pathology [J].
Gibson, PC ;
Cooper, K .
ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (01) :65-69
[10]   Meeting highlights: International consensus panel on the treatment of primary breast cancer [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Coates, AS ;
Senn, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3817-3827